Dr Stephen J Bright
Dr Stephen J Bright
Senior Lecturer of Addiction at Edith Cowan University
Verified email at - Homepage
Cited by
Cited by
Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial
S Ramakrishnan, DV Nicolau Jr, B Langford, M Mahdi, H Jeffers, ...
The Lancet Respiratory Medicine 9 (7), 763-772, 2021
Kronic hysteria: exploring the intersection between Australian synthetic cannabis legislation, the media, and drug-related harm
SJ Bright, B Bishop, R Kane, A Marsh, MJ Barratt
International Journal of Drug Policy 24 (3), 231-237, 2013
What can we say about substance use? Dominant discourses and narratives emergent from Australian media
SJ Bright, A Marsh, LM Smith, B Bishop
Addiction Research & Theory 16 (2), 135-148, 2008
NBOMe—a very different kettle of fish...
DGE Caldicott, SJ Bright, MJ Barratt
The Medical Journal of Australia 199 (5), 322-323, 2013
Synthesis and pharmacology of new psychoactive substance 5F‐CUMYL‐P7AICA, a scaffold‐hopping analog of synthetic cannabinoid receptor agonists 5F‐CUMYL‐PICA and 5F‐CUMYL‐PINACA
SD Banister, A Adams, RC Kevin, C Macdonald, M Glass, R Boyd, ...
Drug testing and analysis 11 (2), 279-291, 2019
Cigarette smoking among young adults: Integrating adolescent cognitive egocentrism with the trans‐theoretical model
SJ Bright, D McKillop, D Ryder
Australian Journal of Psychology 60 (1), 18-25, 2008
Development of an Australian version of the Alcohol‐R elated Problems Survey: A comprehensive computerised screening tool for older adults
SJ Bright, A Fink, JC Beck, J Gabriel, D Singh
Australasian journal on ageing 34 (1), 33-37, 2015
Point prevalence and patterns of mental health comorbidity among people accessing Australia's first older adult–specific alcohol and other drug treatment service
S Bright, K Walsh, C Williams
Journal of Dual Diagnosis 14 (1), 70-75, 2018
Could a drug‐checking service increase intention to use ecstasy at a festival?
S Murphy, SJ Bright, G Dear
Drug and alcohol review 40 (6), 974-978, 2021
Positive drug stories: possibilities for agency and positive subjectivity for harm reduction
LB Engel, SJ Bright, MJ Barratt, MM Allen
Addiction Research & Theory 29 (5), 363-371, 2021
Should Australian psychology consider enhancing psychotherapeutic interventions with psychedelic drugs? A call for research
S Bright, M Williams
Australian Psychologist 53 (6), 467-476, 2018
Australia should be initiating a psychedelic research program: What are the barriers?
N Strauss, SJ Bright, ML Williams
Australian & New Zealand Journal of Psychiatry 50 (11), 1036-1037, 2016
Psychometric properties of the locus of control of behaviour scale (LCBS) among Australians seeking alcohol and other drug (AOD) treatment
SJ Bright, R Kane, A Marsh, B Bishop
Australian Psychologist 48 (3), 172-177, 2013
Development of Australia's first older adult‐specific early intervention for alcohol‐related harm: Feasibility and proof of concept
SJ Bright, CM Williams
Australasian Journal on Ageing 36 (1), 52-55, 2017
Preventing and reducing alcohol-and other drug-related harm among older people: A practical guide for health and welfare professionals
R Nicholas, A Roche, N Lee, S Bright, K Walsh
National Centre for Education and Training on Addiction (NCETA), Flinders …, 2015
International use of screening tools that measure ‘standard drinks’: Whose standard?
S Bright, D Singh, A Fink
Addiction 106 (5), 1022-1023, 2011
Tripping over the other: Could psychedelics increase empathy?
E Blatchford, S Bright, L Engel
Journal of Psychedelic Studies 4 (3), 163-170, 2021
Development of the Australian dominant drug discourses scale
SJ Bright, R Kane, B Bishop, A Marsh
Addiction Research & Theory 22 (5), 416-423, 2014
Should addiction researchers be interested in psychedelic science?
S Bright, M Williams, D Caldicott
Drug and alcohol review 36 (3), 285-287, 2017
New and emerging drugs
S Bright
Australian Drug Foundation, 2013
The system can't perform the operation now. Try again later.
Articles 1–20